NCT03863015View on ClinicalTrials.gov

IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 4, 2019

Primary Completion Date

December 23, 2019

Study Completion Date

June 30, 2020

Conditions
Heart ArrestOut-Of-Hospital Cardiac ArrestSystemic Inflammatory Response Syndrome
Interventions
DRUG

Tocilizumab 20 Mg/mL Intravenous Solution

Tocilizumab is suspended in isotonic saline to a total volume of 100mL prior to infusion

DRUG

isotonic saline

A one hour infusion of 100mL isotonic saline

Trial Locations (1)

2100

Rigshospitalet, Copenhagen

All Listed Sponsors
lead

Christian Hassager

OTHER

NCT03863015 - IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest | Biotech Hunter | Biotech Hunter